{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:58Z","timestamp":1786979938273,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06078-z","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T18:57:41Z","timestamp":1731005861000},"page":"4901-4912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"103","author":[{"given":"Zaheer","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faryal","family":"Altaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimsha","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"6078_CR1","unstructured":"Albagoush SA, Shumway C, Azevedo AM (2023) Multiple Myeloma.\u00a0In: StatPearls [Internet].\u00a0StatPearls Publishing,\u00a0Treasure Island (FL).\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534764\/. Accessed Jan 2024"},{"key":"6078_CR2","unstructured":"Myeloma - Cancer Stat Facts In: SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 24 Jun 2024"},{"key":"6078_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.amjmed.2022.08.030","volume":"136","author":"J Mikhael","year":"2023","unstructured":"Mikhael J, Bhutani M, Cole CE (2023) Multiple myeloma for the primary care provider: a practical review to promote earlier diagnosis among diverse populations. Am J Med 136:33\u201341","journal-title":"Am J Med"},{"key":"6078_CR4","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","volume":"116","author":"AJ Waxman","year":"2010","unstructured":"Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, McGlynn KA, Landgren O (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116:5501\u20135506","journal-title":"Blood"},{"key":"6078_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-40320-5_1","volume":"169","author":"M-V Mateos","year":"2016","unstructured":"Mateos M-V, Landgren O (2016) MGUS and Smoldering multiple myeloma: diagnosis and epidemiology. Cancer Treat Res 169:3\u201312","journal-title":"Cancer Treat Res"},{"key":"6078_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/ITT.S259122","volume":"10","author":"H Hashmi","year":"2021","unstructured":"Hashmi H, Husnain M, Khan A, Usmani SZ (2021) CD38-directed therapies for management of multiple myeloma. Immunotargets Ther 10:201\u2013211","journal-title":"Immunotargets Ther"},{"key":"6078_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/ITT.S240886","volume":"9","author":"O Nadeem","year":"2020","unstructured":"Nadeem O, Tai Y-T, Anderson KC (2020) Immunotherapeutic and targeted approaches in multiple myeloma. Immunotargets Ther 9:201\u2013215","journal-title":"Immunotargets Ther"},{"key":"6078_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C et al (2016) Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 175:252\u2013264","journal-title":"Br J Haematol"},{"key":"6078_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398:314\u2013324","journal-title":"Lancet"},{"key":"6078_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384:705\u2013716","journal-title":"N Engl J Med"},{"key":"6078_CR11","doi-asserted-by":"crossref","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ (2020) B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia\u00a034:985\u20131005","DOI":"10.1038\/s41375-020-0734-z"},{"key":"6078_CR12","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.23.00512","volume":"41","author":"SA Holstein","year":"2023","unstructured":"Holstein SA, Grant SJ, Wildes TM (2023) Chimeric antigen receptor T-Cell and bispecific antibody therapy in multiple myeloma: moving into the future. J Clin Oncol 41:4416\u20134429","journal-title":"J Clin Oncol"},{"key":"6078_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387:495\u2013505","journal-title":"N Engl J Med"},{"key":"6078_CR14","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29:2259\u20132267","journal-title":"Nat Med"},{"key":"6078_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"6078_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u2013605","journal-title":"Eur J Epidemiol"},{"key":"6078_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1258\/1355819021927674","volume":"7","author":"J Higgins","year":"2002","unstructured":"Higgins J, Thompson S, Deeks J, Altman D (2002) Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 7:51\u201361","journal-title":"J Health Serv Res Policy"},{"key":"6078_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"6078_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B et al (2024) Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia 38:365\u2013371","journal-title":"Leukemia"},{"key":"6078_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N et al (2024) Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J 14:35","journal-title":"Blood Cancer J"},{"key":"6078_CR21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ et al (2021) Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398:665\u2013674","journal-title":"Lancet"},{"key":"6078_CR22","doi-asserted-by":"publisher","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis JA, Ahmed N et al (2024) Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. Transplant Cell Ther 30:308.e1-308.e13","journal-title":"Transplant Cell Ther"},{"key":"6078_CR23","doi-asserted-by":"publisher","first-page":"12605","DOI":"10.1182\/blood-2022-158801","volume":"140","author":"K Uttervall","year":"2022","unstructured":"Uttervall K, Nahi H, Kashif M, Lemonakis K, Rosengren S, Brolin J, Lund J, Hansson M (2022) Teclistamab for relapsed\/refractory multiple myeloma: real-world experience in an early access program. Blood 140:12605\u201312606","journal-title":"Blood"},{"key":"6078_CR24","doi-asserted-by":"publisher","first-page":"S506","DOI":"10.1016\/S2152-2650(23)01466-0","volume":"23","author":"SA Maringanti","year":"2023","unstructured":"Maringanti SA, Lin Y, Estritis S et al (2023) MM-527 Real world evaluation of teclistamab for the treatment of relapsed or refractory Multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk 23:S506\u2013S507","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6078_CR25","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1182\/blood-2023-190793","volume":"142","author":"S Asoori","year":"2023","unstructured":"Asoori S, Popat R, Mart\u00ednez-Lopez J et al (2023) Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM). Blood 142:3347","journal-title":"Blood"},{"key":"6078_CR26","doi-asserted-by":"publisher","first-page":"S477","DOI":"10.1016\/S2152-2650(23)01411-8","volume":"23","author":"N van de Donk","year":"2023","unstructured":"van de Donk N, Moreau P, Garfall A et al (2023) MM-163 Long-term follow-up from majesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk 23:S477\u2013S478","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6078_CR27","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/S2152-2650(23)01598-7","volume":"23","author":"C Vegivinti","year":"2023","unstructured":"Vegivinti C, Santhi J, Liu L et al (2023) OA-31 Efficacy of bispecific antibodies in the treatment of extramedullary disease and high risk cytogenetics in relapsed multiple myeloma: a systematic review. Clin Lymphoma Myeloma Leuk 23:S19","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6078_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J et al (2022) Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 12:45","journal-title":"Blood Cancer J"},{"key":"6078_CR29","first-page":"1514","volume":"109","author":"H Hashmi","year":"2024","unstructured":"Hashmi H, Hansen DK, Peres LC et al (2024) Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica 109:1514\u20131524","journal-title":"Haematologica"},{"key":"6078_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167629","volume":"133","author":"MH Robinson","year":"2023","unstructured":"Robinson MH, Villa NY, Jaye DL et al (2023) Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. J Clin Invest 133:e167629","journal-title":"J Clin Invest"},{"key":"6078_CR31","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A et al (2021) Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 12:868","journal-title":"Nat Commun"},{"key":"6078_CR32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0 MC, Dietrich O, Truger M et al (2021) Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med 27:616\u2013619","journal-title":"Nat Med"},{"key":"6078_CR33","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R et al (2023) Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 29:2295\u20132306","journal-title":"Nat Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06078-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06078-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06078-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:13:50Z","timestamp":1735848830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06078-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6078"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06078-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}